Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Berger

Showing results (171-180 of 236) with videos related to

Pageof 24
Sort By:
European Journal of Biochemistry|May 31, 1990
Metabolism and actions of 2-deoxy-2-fluoro-D-galactose in vivoB R Grün, U Berger, F Oberdorfer, et al.
British Journal of Anaesthesia|April 27, 2011
Cognitive function after sevoflurane- vs propofol-based anaesthesia for on-pump cardiac surgery: a randomized controlled trialJ Schoen, L Husemann, C Tiemeyer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Proliferation kinetics and prognosis in gastric cancer after resectionA Sendler, K P Gilbertz, I Becker, et al.
Allergy|March 10, 1998
Effect of continuous allergen challenge on clinical symptoms and mediator release in dust-mite-allergic patientsF Horak, J Toth, R Hirschwehr, et al.
Breast Cancer Research and Treatment|July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapseN Harbeck, C Thomssen, U Berger, et al.
Der Internist|January 15, 2003
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]A Hochhaus, U Berger, A Reiter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapyN Harbeck, U Alt, U Berger, et al.
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Deutsche Medizinische Wochenschrift (1946)|December 4, 2004
[The competence network "acute and chronic leukemias"]R Hehlmann, U Berger, C Aul, et al.
Der Internist|March 9, 2004
[Clinical research in the "acute and chronic leukemias"competence network ]R Hehlmann, U Berger, C Aul, et al.
Pageof 24

Showing results (171-180 of 236) with videos related to

Sort By:
Pageof 24
European Journal of Biochemistry|May 31, 1990
Metabolism and actions of 2-deoxy-2-fluoro-D-galactose in vivoB R Grün, U Berger, F Oberdorfer, et al.
British Journal of Anaesthesia|April 27, 2011
Cognitive function after sevoflurane- vs propofol-based anaesthesia for on-pump cardiac surgery: a randomized controlled trialJ Schoen, L Husemann, C Tiemeyer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Proliferation kinetics and prognosis in gastric cancer after resectionA Sendler, K P Gilbertz, I Becker, et al.
Allergy|March 10, 1998
Effect of continuous allergen challenge on clinical symptoms and mediator release in dust-mite-allergic patientsF Horak, J Toth, R Hirschwehr, et al.
Breast Cancer Research and Treatment|July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapseN Harbeck, C Thomssen, U Berger, et al.
Der Internist|January 15, 2003
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]A Hochhaus, U Berger, A Reiter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapyN Harbeck, U Alt, U Berger, et al.
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Deutsche Medizinische Wochenschrift (1946)|December 4, 2004
[The competence network "acute and chronic leukemias"]R Hehlmann, U Berger, C Aul, et al.
Der Internist|March 9, 2004
[Clinical research in the "acute and chronic leukemias"competence network ]R Hehlmann, U Berger, C Aul, et al.
Pageof 24